Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Spit test could take guesswork out of mental health prescriptions

NCT ID NCT06929533

Knowledge-focused Sponsor: University of Manitoba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study is testing whether a simple saliva test can help doctors prescribe mental health medications more safely and effectively. 200 adults in Manitoba who are starting or changing psychiatric drugs will provide a DNA sample. The results will be shared with their doctor to guide drug choice and dosing. The study focuses on whether this approach is practical and acceptable, not yet on whether it improves health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pharmacogenetic testing (saliva-based DNA test to guide medication choice)
What this could lead to
If successful, this could show that genetic testing helps doctors pick better mental health drugs with fewer side effects, paving the way for wider use.
What could go wrong
This is a small pilot study (200 people) focused on feasibility, not proof of effectiveness. Results may not apply to everyone, and the test may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18 years or older * The initiation, change, dose adjustment, or augmentation of psychotropic medication(s) is indicated * The treating clinician thinks PGx testing can benefit and refers the patient to the study Exclusion Criteria: * Unwillingness to donate saliva samples for genetic analysis * History of liver or bone marrow (hematopoietic cell) transplantation * PGx testing results are already available * No personal health identification number (PHIN) is available

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug reaction (ADR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder bipolar disorder Depression Drug-Related Side Effects and Adverse Reactions mental disorder psychiatric disorder Psychological Well-Being Psychotic Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug reaction (ADR) Effectiveness Mental disorder Pharmacogenetics

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shared Health Facilities

    NOT_YET_RECRUITING

    Winnipeg, Manitoba, R3C 3H8, Canada

  • University of Manitoba College of Pharmacy

    RECRUITING

    Winnipeg, Manitoba, R3E 0T5, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.